Your browser doesn't support javascript.
loading
HBV continuum of care using community- and hospital-based screening interventions in Senegal: Results from the PROLIFICA programme.
Sow, Amina; Lemoine, Maud; Toure, Papa Souleymane; Diop, Madoky; Lo, Gora; De Veiga, Jean; Pape, Omar Thiaw; Seck, Khady; Ndow, Gibril; Bojang, Lamin; Kane, Arame; Oudiane, Marina; Howell, Jess; Nayagam, Shevanthi; Moutchia, Jude; Chemin, Isabelle; Mendy, Maimuna; Toure-Kane, Coumba; Thursz, Mark; Ka, Mourtalla; Shimakawa, Yusuke; Mboup, Souleymane.
Afiliação
  • Sow A; Institut de Recherche en Santé de Surveillance Epidemiologique et de Formation (IRESSEF) Laboratoire CHNU Dalal Jamm Guediawaye, IRESSEF Diamnoadio Dakar, Senegal.
  • Lemoine M; Laboratoire de Virology, Hopital Le Dantec, Dakar, Senegal.
  • Toure PS; Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Section of Hepatology, St Mary's Hospital, Imperial College London, London, UK.
  • Diop M; Medical Research Council the Gambia Unit at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
  • Lo G; UFR des Sciences de la Sante, Thies, Senegal.
  • De Veiga J; Centre hospitalier de Tivaoaune, Service de Medecine interne, Thies, Senegal.
  • Pape OT; UFR des Sciences de la Sante, Thies, Senegal.
  • Seck K; Institut de Recherche en Santé de Surveillance Epidemiologique et de Formation (IRESSEF) Laboratoire CHNU Dalal Jamm Guediawaye, IRESSEF Diamnoadio Dakar, Senegal.
  • Ndow G; Laboratoire de Virology, Hopital Le Dantec, Dakar, Senegal.
  • Bojang L; Hopital Saint Jean de Dieu, Service d'Hepatologie et Gastroenterologie, Thies, Senegal.
  • Kane A; Hopital Saint Jean de Dieu, Laboratoire d'analyse biochimique et hématologique, Thies, Senegal.
  • Oudiane M; Centre hospitalier régional de Thies, Service de Medecine interne, Thies, Senegal.
  • Howell J; Medical Research Council the Gambia Unit at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
  • Nayagam S; Medical Research Council the Gambia Unit at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
  • Moutchia J; UFR des Sciences de la Sante, Thies, Senegal.
  • Chemin I; Centre hospitalier de Tivaoaune, Service de Medecine interne, Thies, Senegal.
  • Mendy M; UFR des Sciences de la Sante, Thies, Senegal.
  • Toure-Kane C; Centre hospitalier de Tivaoaune, Service de Medecine interne, Thies, Senegal.
  • Thursz M; Disease Elimination, Burnet Institute, Department of Gastroenterology, St. Vincent's Hospital Department of Epidemiology and Preventive Medicine, Monash University Melbourne, Melbourne, Victoria, Australia.
  • Ka M; Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Section of Hepatology, St Mary's Hospital, Imperial College London, London, UK.
  • Shimakawa Y; MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
  • Mboup S; Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur Paris, France.
JHEP Rep ; 4(10): 100533, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36052221
ABSTRACT
Background &

Aims:

Strategies to implement HBV screening and treatment are critical to achieve HBV elimination but have been inadequately evaluated in sub-Saharan Africa (sSA).

Methods:

We assessed the feasibility of screen-and-treat interventions in 3 real-world settings (community, workplace, and hospital) in Senegal. Adult participants were screened using a rapid HBsAg point-of-care test. The proportion linked to care, the proportion who had complete clinical staging (alanine transaminase [ALT], viral load, and FibroScan®), and the proportion eligible for treatment were compared among the 3 intervention groups.

Results:

In 2013-2016, a total of 3,665 individuals were screened for HBsAg in the community (n = 2,153) and in workplaces (n = 1,512); 199/2,153 (9.2%) and 167/1,512 (11%) were HBsAg-positive in the community and workplaces, respectively. In the hospital setting (outpatient clinics), 638 HBsAg-positive participants were enrolled in the study. All infected participants were treatment naïve. Linkage to care was similar among community-based (69.9%), workplace-based (69.5%), and hospital-based interventions (72.6%, p = 0.617). Of HBV-infected participants successfully linked to care, full clinical staging was obtained in 47.5% (66/139), 59.5% (69/116), and 71.1% (329/463) from the community, workplaces, and hospitals, respectively (p <0.001). The proportion eligible for treatment (EASL criteria) differed among community- (9.1%), workplace- (30.4%), and hospital-based settings (17.6%, p = 0.007). Acceptability of antiviral therapy, adherence, and safety at 1 year were very good.

Conclusions:

HBV screen-and-treat interventions are feasible in non-hospital and hospital settings in Senegal. However, the continuum of care is suboptimal owing to limited access to full clinical staging. Improvement in access to diagnostic services is urgently needed in sSA. Lay

summary:

Hepatitis B infection is highly endemic in Senegal. Screening for infection can be done outside hospitals, in communities or workplaces. However, the hepatitis B continuum of care is suboptimal in Senegal and needs to be simplified to scale-up diagnosis and treatment coverage.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: JHEP Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Senegal

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: JHEP Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Senegal
...